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Objectives: To find out the average direct hospitalization cost and length of hos-
pital stay for patients infected with Carbapenem-resistant Klebsiella pneumonia 
(CRKp) and compare it with that of patients infected with Carbapenem-sensitive 
Klebsiella pneumonia (CSKp). MethOds: A cross sectional study was carried out 
from January-December 2014 and the data for hospitalization cost was collected for 
the patients with CRKp and CSKp infections from the medicine ICU for 72 patients 
admitted to the hospital. The data was analyzed for the site of infection, length of 
stay and average direct hospitalization cost which was then compared between the 
two groups. Results: During the study period, 101 patients were diagnosed with 
Klebsiella pneumoniae infection. 61.79% of the infections were respiratory, 24.52% 
urinary tract- related, 13.2% systemic and 0.47% skin and soft tissue-related. The 
mean age of the study population was 51.7 ± 15.7 years. The median length of stay 
for CRKp was 12 (11; 23) days as compared to 8 (5.2; 13.2) days in CSKp patients . The 
median direct hospitalization cost was calculated to be INR 43,274 (24,898; 16,0315) 
in case of CRKp versus INR 23,452 (12,489; 47,349) in CSKp patients. cOnclusiOns: 
We observed that the average cost of overall therapy and the average no. of hos-
pitalization days was higher in CRKp group compared to CSKp group. Antibiotic 
resistance is a growing phenomenon and the resistance to Carbapenems can lead 
to increased burden of morbidity and treatment cost for patients.
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Objectives: Antibiotic resistance is known to be associated with increased burden 
of morbidity, mortality and treatment costs all over the world. Methicillin resistant 
Staphylococcus aureus is one of the most important gram positive bacteria which 
causes serious community acquired as well as hospital acquired infections. The 
objective of this study is to compare the direct costs and length of stay in MRSA ver-
sus MSSA infections among in-patients of the hospital. MethOds: A cross sectional 
study was carried out from Jan-Dec 2013 and the hospitalization cost was collected 
for the patients with MRSA and MSSA infections from the medicine ICU and the 
microbiology department for 63 patients. The data was analyzed for the type of 
infection and the average hospitalization cost. The median hospitalization cost was 
calculated for both the group of patients. Results: Out of the 63 patients observed, 
44 (69.84%) patients were infected with MRSA and 19 (30.15%) were infected with 
MSSA. The median length of stay was 10 days in MRSA group as compared to 
7.5 days in MSSA group. The median hospitalization cost for MRSA infection was 
INR 16,383 and for MSSA it was INR 11,481. cOnclusiOns: Methicillin resistance in 
Staphylococcus aureus is associated with increased length of stay and hospitaliza-
tion costs. Increased length of stay leads to further increase in the treatment costs 
and morbidity of the patients as it may lead to nosocomial infections.
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Objectives: To compare the cost of the primary prophylaxis of invasive fungal infec-
tions (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing 
allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National 
Health System (NHS) in Spain. MethOds: A cost analysis was made for 100 days and 
180 days of prophylaxis and a decision tree model was developed. The efficacy rate 
of IFI prophylaxis, mortality rate from all causes in patients with/without IFI and 
survival rate with liposomal amphotericin B treatment of prophylaxis failures were 
obtained from randomized trials and a mixed treatment comparisons meta-analysis. 
The model simulation was interrupted with IFI treatment (prophylaxis failures). The 
costs of medication and its intravenous administration in the hospital (in the case of 
micafungin) were considered. Results: In the non-modeled analysis, the savings 
per patient of prophylaxis with voriconazole ranged from € 1,709 to € 9,655 compared 
with posaconazole oral solution, from € 1,811 to € 9,767 compared with posacona-
zole gastro-resistant tablets and from € 3,376 to € 7,713 compared with micafungin. 
In the modeled analysis, the mean cost per patient of the prophylaxis and treatment 
of IFIs was € 6,987 to € 7,619 with voriconazole, € 7,749 with posaconazole, and € 
22,424 with micafungin. Therefore, the savings per patient of prophylaxis with vori-
conazole was € 130 to € 3,664 and € 11,132 to € 30,374 compared with posaconazole 
and micafungin, respectively. The result remained stable after modification of the 
number of days of antifungal prophylaxis and the cost of antifungal treatment of 
failures. cOnclusiOns: According to the model, antifungal prophylaxis with vori-
conazole in recipients of hematopoietic progenitor transplants, compared with posa-
conazole or micafungin, may represent savings for NHS hospitals in Spain.
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Objectives: Darunavir and atazanavir are currently the only protease inhibitors 
(PIs) recommended by the British HIV Association (BHIVA) treatment guidelines. The 
Office of AIDS Research Advisory Council (OARAC) reviewed the US HIV guidelines 
in April 2015 and delisted atazanavir/ritonavir (ATV/r) from the preferred PI options 
as a result of better tolerability (primarily due to discontinuations caused by adverse 
events (AEs)) of darunavir/ritonavir (DRV/r) compared to ATV/r based on findings from 
the ARDENT trial. The objective of this analysis was to quantify the economic impact 
of treating patients with DRV/r compared to ATV/r for two years in the UK based on 
drug costs, AEs and discontinuation due to AEs. MethOds: A simple Markov model 
was built in MS Excel with two health states and 6-month cycles (4 cycles in total): 
on treatment with DRV/r or ATV/r and on subsequent treatment. All patients start on 
DRV/r or ATV/r and some discontinue and move to a subsequent therapy (weighted 
average of 3rd agents in treatment experienced patients, £11.10/day at list price). 
Discontinuation rates from ARDENT were converted to 6-month rates (4.60% for DRV/r 
and 8.78% for ATV/r) using the method from Miller et al. Patients were assumed to 
attend 6 further consultant appointments (£325/visit) in the first three months after 
switching as advised in the BHIVA guidelines for monitoring. AEs from ARDENT were 
also included. Results: Using a list price of £10.57/day for DRV/r and £10.76/day for 
ATV/r), treatment with DRV/r saved £116 per patient in 6 months, £219 in one year 
and £393 over two years. Drivers of savings were the cost of consultant appointments 
and of subsequent treatment. Sensitivity analyses showed how DRV/r was cost saving 
even when the drug cost of DRV/r and ATV/r was assumed equal. cOnclusiOns: In 
conclusion DRV/r has proven to be a highly tolerable and cost saving PI.
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Objectives: Treatment of chronic hepatitis C is changing fast given the amount 
of new drugs coming to the market. Little is known about the budget impact and 
long term implications of the different treatment options. The objective of this 
study was to estimate the budget impact of different treatment options on national 
or regional level and to evaluate the short-term as well as long-term implications 
of different hepatitis C treatments. MethOds: A model flexible for regional and 
national Swedish cohorts of hepatitis C patients was developed. Cost and effect 
inputs were taken from published sources and clinical trial data. Using the model, 
total budget impact as well as cost per cured patient was estimated for different 
treatments. In addition, long term consequences of different treatments were esti-
mated using a Markov model with transition probabilities from the published model 
in the field by Lidgren et al.(1) Results: Given efficacy rates of over 95%, the new 
treatments of hepatitis C will cure more patients in Swedish cohorts compared to 
previous treatments with efficacy rates of around 65%. In the long term, the supe-
rior effectiveness of the new treatments would translate into decreases in cases of 
decompensated cirrhosis, hepatocellular cancer and liver transplants of over 90% 
among these patients. cOnclusiOns: The new treatments of hepatitis C could 
improve virologic outcomes among patients. In the long term, cost-savings from 
reduced burden of disease among these patients are also to be expected. However, 
in the short term these treatments will require twice the budget size compared to 
earlier antiviral therapies in this field. (1.) Lidgren M, Hollander A, Weiland O, Jonsson 
B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, 
cost-effectiveness and quality of life. Scand J Gastroenterol. 2007 Jul;42(7):876-77
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Objectives: To obtain long-term outcomes of using rilpivirine/tenofovir/emtricit-
abine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 
copies/ml in the Russian Federation. MethOds: Cost analysis was based on the 
results of modeling the treatment of naïve HIV-infected patients with rilpivirine/
tenofovir/emtricitabine (single tablet regimen). Present analysis included assessment 
of direct (ambulatory treatment and hospitalization) and indirect costs (GDP losses). 
Cost data was based on median prices for medicines and medical services in National 
healthcare system in the Russian Federation. Results: The use of rilpivirine/tenofo-
vir/emtricitabine (single tablet regimen) in the analyzed population, due to the better 
adherance and, as a result, better viral suppression, leads to the lower number of new 
HIV-infected persons. Therefore in life-time perspective the potential total costs sav-
ings for the whole population can be up to 8% (€ 1 116 010 172) and 6% (€ 841 581 441) 
compared to efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + 
tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Obtained 
results showed that better adherence on the treatment scheme rilpivirine/tenofovir/
emtricitabine (single tablet regimen) among naïve patients with HIV-1 RNA< 100 000 
copies/ml can lead to potential significant long-term cost savings.
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Objectives: According to World Health Organization, influenza and acute respira-
tory infections (ARI) affect more than 30% of the population each year. In Ukraine the 
burden of costs for medicines are mainly paid by patients out of pocket. MethOds: 
We analyzed the statistics of the Ministry of Health of Ukraine, the incidence of 
influenza and ARI, the Protocol for diagnosis and treatment of novel influenza A 
(H1 / N1) (CA) in adults in Ukraine and used the pharmacoeconomic method «Cost 
of illness». Results: We received that number of outpatients were in 2009-2010 
(Nov- May, Pandemic) - 7,753,635 sick persons, 2010-2011 (Oct 2010 - Apr. 2011) - 
7,502,008, 2011-2012 - 5,584,518, 2012-2013 – 6,200,000, 2013-2014 – 6,015,000, respec-
tively. Based on these data, we found that in 2014 the number of cases decreased 
by almost 1, 5 million compared with 2010. Now we compared the direct costs on 
outpatient treatment in 2014 and 2010. The direct cost per patient of influenza and 
ARI in 2010 amounted to 80,39 UAH. We estimated the total costs were 60386423 
UAH. Direct costs for outpatient costs consist of expenses for medicines and doc-
tor’s consultations. The direct cost per patient of influenza and ARI in 2014 totaled 
221,07 UAH. Cost of Illness was 1329751087 UAH. This situation is connected with 
the rising prices of drugs through the exchange rate in Ukraine in 2014. Financing of 
medicines by 90% are of own patient funds. In Ukraine established the some groups 
which drugs are dispensed free of charge or concessional. They represent the range 
of 10% of all patients. cOnclusiOns: High costs for treatment of influenza and 
ARI should reimburse by state and it’s need the monitoring the incidence and to 
evaluate indirect costs.
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Objectives: Malaysia is experiencing an escalation of dengue epidemic activity. 
The candidate vaccine currently at the most advanced stage of development has 
demonstrated its efficacy in two large scale efficacy studies. This study aims to 
estimate the potential health and economic impact of the vaccine in Malaysia 
under different vaccination strategies. MethOds: A dengue dynamic transmis-
sion mathematical model was employed to evaluate the impact of dengue vaccina-
tion program on the incidence, mortality and economic burden of the disease. The 
model was calibrated and validated with Malaysia specific epidemiological data 
and vaccine efficacy data from phase-III efficacy studies. The impact was evalu-
ated over a 10-year period from provider perspective. Two vaccination strategies, 
targeted-hotspots (THS, covered population in 6 selected hotspot districts) and 
nationwide (NW, covered the whole Malaysian population), were simulated. Both 
strategies comprised of routinely vaccinated children aged 13 and a catch-up 
cohort from ages 14 to 30 who were vaccinated over a 1 year duration. Probabilistic 
and univariate sensitivity analyses on key parameters were conducted to examine 
uncertainty in the model. All costs were expressed in 2013 USD. Results: The cost 
per dengue case from provider perspective was USD999.02. The model predicted 
that dengue vaccination under the THS strategy would prevent 448,124 [95%CI: 
292,875; 632,375] dengue cases, 509 [95%CI: 335; 707] dengue-related deaths, 11,785 
[95%CI: 7,888; 16,329] life years lost and 16,751 [95%CI: 11,128; 23,281] DALYs. 
Nationwide vaccination would prevent 1,060,222 [95%CI: 694,181; 1,490,929] den-
gue cases, 1,202 [95%CI: 797; 1,672] dengue-related deaths, 27,834 [95%CI: 18,756; 
38,501] life years lost and 39,584 [95%CI: 26,464; 54,968] DALYs. The total dengue 
treatment cost saved for THS and NW vaccination strategy were USD163,859,846 
[95%CI: 109,093,124; 235,805,776] and USD386,962,641 [95%CI: 257,410,189; 
557,347,377] respectively. cOnclusiOns: We conclude that dengue vaccination 
would significantly reduce the disease and economic burden in Malaysia, espe-
cially if it is introduced during current dengue epidemic.
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Objectives: Outpatient parenteral antimicrobial therapy (OPAT) is a strategic 
delivery modality of care however cost-analysis should support decision-making. 
This study was performed in order to analyze the economic studies related to 
OPAT MethOds: a systematic review was performed with the following search 
terms: outpatient (Population), anti-infective agents, infusion therapy or home care 
(Intervention), inpatient (Comparator), complications related to infection, cure, read-
mission, catheter infection, death (Outcome), and economic analysis (Study design). 
Publications were searched from health sciences databases (MEDLINE, Embase, 
The Cochrane Library, Lilacs, Bireme, Medscape, Trip database, Web of Science), 
health technology evaluation sites and gray literature (dissertation abstracts), inde-
pendently of publication´s year or idiom. Three different reviewers evaluated the 
manuscripts in a systematic progressive process beginning from title followed by 
abstract and complete reading for quality of evidence. Results: 655 publications 
were identified according to PICOS proposed. Of this, 9 studies developed in eight 
different countries, from 2001 to 2014, were included for analysis. OPAT regimen 
was based on infusion center at five (combined with home care in three) and home 
care exclusively in four studies. The perspective of cost analysis was of the hospital 
by seven sites, health care system in one, hospital combined to health care system 
in one and payer by the other one. The type of analysis was cost-consequence in 
Objectives: To estimate the annual average per patient cost for diagnosing and 
treating chronic hepatitis B (CHB) and its complications in three large metropoli-
tan cities in India. MethOds: Health resources consumed during the diagnosis 
and treatment of CHB and its complications were estimated by administering a 
structured survey to a total of 30 participating physicians from 3 cities (8 hepa-
tologist/gastroenterologist and 2 oncologist treating hepatocellular carcinoma 
patients per city). Equal number of physicians from private and central govern-
ment health scheme hospitals (CGHS) participated in the survey. Cost for labora-
tory tests, imaging, procedures, hospital admissions, physician visits, and drugs 
received on an inpatient and outpatient basis were estimated using rates provided 
by private setting centres and CGHS approved rates in the 3 cities. Mean, median, 
standard deviation, and frequency were used to analyze data. Results: Total 
annual average cost for treating CHB, compensated cirrhosis, decompensated 
cirrhosis, and hepatocellular carcinoma (HCC) were INR 79,768 (USD 1,269), INR 
53,223 (USD 846), INR 3,99,316 (USD 6,355), and INR 5,069,12 (USD 8,067) in a pri-
vate hospital and INR 49,796 (USD 792), INR 33,976 (USD 538), INR 2,73,564 (USD 
4,353), and INR 358,071 (USD 5,698) in a CGHS hospital, respectively. The added 
inpatient cost of undergoing liver transplant for eligible HCC patients was on 
an average INR 25,00,000 (USD 39,783). cOnclusiOns: Findings from our study 
provide an initial understanding of the magnitude of direct medical cost burden 
that CHB and its complications impose on patients in India. The results high-
light the increasing health-care cost related to disease progression which can 
be potentially reduced by effective prevention strategies, early treatment, and 
patient education to improve adherence to treatment. Future efforts should focus 
on conducting large observational studies using patient level data and develop 
models to support uptake of cost-effective strategies to manage the burden of CHB 
in India.
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Objectives: The aim of this study was to estimate health and medical care costs 
for hospitalized pneumonia among children < 2 years of age, pre- and post the 
introduction of Prevenar13 (PCV13) in Sweden. MethOds: The incidence of inpa-
tient all-cause pneumonia (ICD-10 J12-J18) by County Council among children 
< 2 years old between 1998 and 2013 was identified using the Swedish National 
Inpatient Register. The average incidence of pneumonia was calculated among 
County Councils that were utilizing PCV13 in two periods; the pre PCV period 
(during 1998-2006) and the post PCV 13 period (during 2011-2013). In a subsequent 
step, the average incidence per 100 000 by calendar period was multiplied with 
the expected costs of inpatient pneumonia (34 524 SEK, 3 712 € ) Results: The 
mean rates of all-cause pneumonia hospitalizations per 100,000 person years 
were higher in the pre-PCV13 era compared to after the introduction of PCV13 in 
Sweden (pre-PCV13; 596.4 and post-PCV13; 455.7 per 100,000 person years, respec-
tively). A difference of almost 5 million SEK (538 000€ ), in health and medical care 
costs per 100,000 person years was observed during the pre and post introduc-
tion of PCV13 among County Councils that were utilizing PCV13 between 2011 
and 2013. cOnclusiOns: Among children < 2 years old, all-cause pneumonia 
hospitalizations were reduced after introduction of PCV13 vaccination in Sweden. 
A reduction in the incidence of pneumonia also reduced the health and medical 
care costs.
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Objectives: The aim of this study was (1) to assess the epidemiologic profile of CDI 
in England and Merseyside in the last decade and (2) to estimate the costs associ-
ated with CDI episodes through successive seasons (2008-2012) in a large hospital 
setting (Royal Liverpool & Broadgreen University Hospitals). MethOds: (1) National 
figures for incidence and CDI-associated deaths were obtained from the Office for 
National Statistics and the Public Health England. (2) Clinical and epidemiologi-
cal information was obtained from 397 consecutive CDI and antibiotic-associated 
diarrhoea (AAD) patients assessed by medical staff and recruited by a prospective 
study. Costs were obtained through the determination of hospital stay and the 
most relevant Healthcare-Resource-Group (HRG) recorded for the disease period 
until their discharge/death. Generalised linear models with gamma distribution 
were employed for the multivariate analysis. Results: A CDI epidemic season was 
evident between 2005 and 2010, reaching its peak during the 2007/2008 season fol-
lowing by an endemic phase (2011/2012 onwards). Between 2009-2013 when national 
figures became available, Northern and Western regions displayed the highest inci-
dence and death rates. Within Merseyside, Liverpool had the highest incidence 
of all. Significantly higher incidence rates of CDI were generally correlated with 
index-of-multiple-deprivation (IMD), which was particularly higher in Merseyside 
than the national average. Mean costs for cases were significantly higher (£14,424.07) 
than controls (£3467.25). Pre-test costs and low Albumin levels were statistically 
significant predictor of CDI costs. cOnclusiOns: CDI was indeed associated with 
increased overall hospitalisation costs. However, the extent to which CDI per se pro-
longs hospitalisation remains an objective as comorbidities and underlying condi-
tions (denoted by pre-test costs) were the strongest predictors. Further work is being 
conducted to disentangle the impact of other significant contributing factors, and 
the use of HRGs will be compared to Patient-Level-Information-and-Costs-System 
(PLICS) using a replication set of patients.
